• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

Merck, seeking XI factor in race with Bayer, gets FDA fast-track tag for anticoagulant

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Aug 23, 2022 at 11:02: AM
via The FDA has delivered a boost to Merck’s mission to provide a standard-of-care anticoagulation therapy for end-stage renal disease (ESRD) patients by slapping a fast-track tag on midphase asset MK-2060.

article source
 

<



Similar threads

cafead
FDA Approves Merck’s Keytruda for First-Line Treatment of Pleural Mesothelioma
Replies
0
Views
19
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Daiichi Sankyo-Merck&#039;s &#039;guided-missile&#039; cancer drug meets main goal in late-stage trial
Replies
0
Views
6
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
ESMO: Despite checkered past, Merck&#039;s Keytruda-Lenvima pairing looks to change practice in liver cancer subtype
Replies
0
Views
26
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
ESMO: Despite positive trial, Merck&#039;s Welireg still comes up short in overall survival
Replies
0
Views
18
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Merck, Daiichi repeat early success in small cell lung cancer with updated ADC data
Replies
0
Views
31
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote